Sun Pharma Quiz: Test Your Industry Knowledge Now

Sun Pharma began its global expansion in 1997 with its very first international acquisition of a US-based generic drug manufacturer. This strategic move gave Sun Pharma access to FDA-approved facilities, regulatory expertise, and an established American distribution network.

Sun Pharma pursued an Israel-based specialty dermatology company for years before finally securing a controlling stake in 2010. The acquisition involved prolonged legal disputes across multiple jurisdictions but gave Sun Pharma a strong foothold in high-margin dermatology markets.

In 1996, Sun Pharma acquired a pharmaceutical manufacturing plant from Knoll Pharmaceuticals, a subsidiary of the German chemical giant BASF. Buying an existing operational facility was faster and more cost-effective than constructing a brand-new manufacturing unit independently.

An Active Pharmaceutical Ingredient, or API, is the compound in any medicine responsible for its therapeutic effect. Sun Pharma established a dedicated API plant in Panoli, located in Gujarat's industrially significant Bharuch district, to strengthen vertical integration and supply security.

In 2007, Sun Pharma created a separately listed R&D subsidiary focused exclusively on innovative drug discovery. This entity works on new chemical entities, novel drug delivery systems, and differentiated specialty therapies spanning oncology, dermatology, and ophthalmology.